Illumina Shares Hit a 10-Year Low as the Company's Customers Pull Back on Spending
Illumina (ILMN) shares fell to their lowest level in a decade after the genetic research equipment manufacturer missed revenue estimates and slashed its guidance as customers pulled back on spending.
Illumina's stock on track for lowest close in 10 years after cutting guidance
Illumina Inc.'s stock ILMN, -13.91% fell 14% Friday to put it on track for its lowest close in 10 years, after the company after the maker of DNA-sequencing technology cut its full-year sales and p...
Illumina stock drops on another earnings warning
Illumina Inc (NASDAQ:ILMN) shares sank 11% in pre-market trading on Friday after the gene-testing company reduced its annual profit forecast for the second straight quarter, citing weakness in dema...
Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut
Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.
Illumina, Inc. (ILMN) Q3 2023 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q4 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive...
Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall...
Illumina cuts annual profit forecast for second straight quarter
U.S. genetic testing Illumina on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by weakness in demand for its sequencing instruments, consumables and services.
Illumina shares fall as company cuts forecasts
Shares of Illumina Inc. ILMN, -3.36% fell after hours on Thursday after the maker of DNA-sequencing technology cut its full-year sales and profit outlook. The company said it now expected full-year...
Seeking Clues to Illumina (ILMN) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for th...
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Activist Icahn sues Illumina board over Grail acquisition - FT
Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing company Grail , the Financial Times reported on Tues...
Illumina responds to EC Grail divestiture order
Illumina Inc. ILMN, -1.10% responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 billion acquisition of cancer-test maker Grail. Il...
Illumina to divest cancer test maker Grail if it does not win challenge in EU court
Illumina said on Friday it would divest cancer test maker Grail in 12 months, according to the terms of the order by the European Commission, if it does not win its challenge in court.
Illumina ordered by European Commission to sell cancer test maker Grail
Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the cancer test maker before securing their approval. ...
Illumina ordered by EU antitrust regulators to sell Grail
U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before securing their approval.
Related Companies